EAEva Arneric

Eva Arneric

*This is an algorithmically generated author record based on publicly available information.

Eva Arneric has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient selection and workflow optimisation for ‎fiducial-free 2-View tracking in CyberKnife lung stereotactic radiotherapy

    by Milad Mirzaei, Nicholas Bucknell, Mahsheed Sabet, Jake Kendrick, Adriano Polpo, Eva Arneric, Angela Jacques, Joshua Dass, Sean Bydder, Martin Ebert, et al.

    PurposeThe CyberKnife® (CK) Synchrony® Xsight® Lung Tracking System (XLTS) ‎enables non-invasive soft tissue-based respiratory tracking as an alternative to fiducial implantation for lung ‎stereotactic body radiotherapy (SBRT). Patient selection has relied on clinician ‎judgment, often resulting in unsuccessful simulations and ‎treatment delays. This study evaluated fiducial-free CK simulation outcomes, identified predictors of successful 2-View tracking, and developed evidence-based patient selection framework.Methods and materialsThirty consecutive patients undergoing fiducial-free CK ‎simulation between April 2022 and March 2024 were ‎retrospectively analysed. Simulation outcomes were classified as 2-View, 1-View, or 0-View based ‎on live X-ray image correlation. Tumour location, diameter, volume, ‎‎density (Hounsfield units), X-ray technique, and axial position ‎were assessed for association ‎with successful 2-View tracking.ResultsSuccessful 2-View tracking was achieved in 33.3% of simulations, while 23.4% and 43.3% resulted in 1-View and 0-View outcomes, respectively. Simulation failure was more frequent in tumours <15 mm, centrally located lesions, or those adjacent to the diaphragm. Successful 2-View tracking was associated with larger tumour volume (mean 4.7 vs 1.6 cm3, p = 0.028) and higher maximum tumour density (67.5 vs 56.0 HU, p = 0.029).ConclusionsThis study evaluated fiducial-free CK simulation to support more consistent patient selection for ‎lung SBRT. Tumour location, diameter, and density may help predict tracking success and reduce unsuccessful simulations. These findings provide a practical framework to guide fiducial use and lay the groundwork for future predictive models to identify, at an early stage, patients likely to require fiducial implantation at biopsy.